{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:41:59Z","timestamp":1788777719070,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NCT05526755"],"award-info":[{"award-number":["NCT05526755"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cllc.2023.09.005","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T04:37:22Z","timestamp":1696394242000},"page":"80-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-3997","authenticated-orcid":false,"given":"Ross Andrew","family":"Soo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chung-Man","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Servidio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sandelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2023.09.005_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2023.09.005_bib0002","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1378\/chest.123.6.2096","article-title":"Preoperative evaluation of patients undergoing lung resection surgery","volume":"123","author":"Datta","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2023.09.005_bib0003","doi-asserted-by":"crossref","first-page":"vii196","DOI":"10.1093\/annonc\/mdq376","article-title":"Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?","volume":"21","author":"Le Chevalier","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0004","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.5858\/arpa.2013-0319-CR","article-title":"Lung cancer biomarkers: present status and future developments","volume":"137","author":"Cagle","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cllc.2023.09.005_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0006","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/1759-7714.12651","article-title":"EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: analysis based on large-scale data from China","volume":"9","author":"Pi","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2023.09.005_bib0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2022.12.010","article-title":"Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: implications for adjuvant therapy","volume":"181","author":"Hondelink","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2023.09.005_bib0008","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2023.09.005_bib0009","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2023.09.005_bib0010","doi-asserted-by":"crossref","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, et\u00a0al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u20131061.","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"10.1016\/j.cllc.2023.09.005_bib0011","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.09.005_bib0012","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.09.005_bib0013","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0014","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.09.005_bib0015","unstructured":"U.S Food and Drug Administration. Highlights of Prescribing Information. TAGRISSO\u00ae (osimertinib) Tablets, for Oral Use. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208065s025lbl.pdf. Accessed: May 25, 2023, 2023."},{"key":"10.1016\/j.cllc.2023.09.005_bib0016","unstructured":"European Medicines Agency. Summary of Product Characteristics. TAGRISSO\u2122 (osimertinib) 40 mg\/80mg film-coated tablets. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tagrisso-epar-product-information_en.pdf. Accessed: May 25, 2023, 2023."},{"key":"10.1016\/j.cllc.2023.09.005_bib0017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.22.00051","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO guideline rapid recommendation update","volume":"40","author":"Pisters","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0018","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0019","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.09.005_bib0021","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0022","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.3.2023. \u00a9 National Comprehensive Cancer, Inc. 2023. All rights reserved. Accessed July 26, 2023. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way"},{"key":"10.1016\/j.cllc.2023.09.005_bib0023","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.2017.72.4401","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology\/Cancer Care Ontario Clinical Practice Guideline update","volume":"35","author":"Kris","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0024","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0025","unstructured":"European Medicines Agency. TECENTRIQ\u00ae (atezolizumab) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf. Accessed: September 22, 2023, 2023."},{"key":"10.1016\/j.cllc.2023.09.005_bib0026","unstructured":"U.S Food and Drug Administration. OPDIVO\u00ae (nivolumab) Highlights of Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125554s112lbl.pdf. Accessed: May 25, 2023."},{"key":"10.1016\/j.cllc.2023.09.005_bib0027","unstructured":"European Medicines Agency. OPDIVO\u00ae (nivolumab) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed: May 25, 2023."},{"key":"10.1016\/j.cllc.2023.09.005_bib0028","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","article-title":"Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC","volume":"18","author":"Naidoo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0029","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jtho.2021.04.003","article-title":"Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?","volume":"16","author":"Qiao","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0030","doi-asserted-by":"crossref","first-page":"751209","DOI":"10.3389\/fonc.2021.751209","article-title":"Role of immune checkpoint inhibitor therapy in advanced EGFR-mutant non-small cell lung cancer","volume":"11","author":"Wiest","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0031","doi-asserted-by":"crossref","first-page":"940288","DOI":"10.3389\/fimmu.2022.940288","article-title":"Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: current status, possible mechanisms and application prospects","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231161409","article-title":"Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer","volume":"15","author":"Vokes","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2023.09.005_bib0033","doi-asserted-by":"crossref","first-page":"CT005","DOI":"10.1158\/1538-7445.AM2023-CT005","article-title":"Abstract CT005: AEGEAN: a phase 3 trial of neoadjuvant durvalumab\u00a0+\u00a0chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC","volume":"83","author":"Heymach","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2023.09.005_bib0034","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.09.005_bib0035","series-title":"World Conference on Lung Cancer. International Association for the Study of Lung Cancer","article-title":"Neoadjuvant durvalumab\u00a0+\u00a0chemotherapy followed by adjuvant durvalumab in resectable EGFR-mutated NSCLC (AEGEAN)","author":"He","year":"2023"},{"key":"10.1016\/j.cllc.2023.09.005_bib0036","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/88.21.1543","article-title":"Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer","volume":"88","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2023.09.005_bib0037","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2023.09.005_bib0038","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2023.09.005_bib0039","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/atm.ATM_110_19","article-title":"Lung nodules: a comprehensive review on current approach and management","volume":"14","author":"Loverdos","year":"2019","journal-title":"Ann Thorac Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:09:12Z","timestamp":1778616552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1525730423001900"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.09.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}